RTP Mobile Logo
New Agents and Emerging Strategies in the Management of Uterine Sarcomas
Released May 2018

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Suzanne George, Martee L Hensley and David M O’Malley. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

    As a group, gynecologic sarcomas are relatively rare, and given their wide heterogeneity, specific histologic subtypes present even less frequently in clinical practice. As such, gynecologic and medical oncologists may lack experience caring for patients with any given uterine sarcoma, including the most common, uterine leiomyosarcoma (uLMS). Even so, and despite the fact that conventional treatment options for sarcomas of the female genital tract had remained unchanged for several years, recently published research has led to several newly approved therapies poised to disrupt established standards. With the proliferation of these research advances, it is important for any healthcare professional involved in the care of these individuals to remain up to date in order to appropriately offer patients with uLMS or other gynecologic sarcomas high-quality treatment.

    As such, these video proceedings from a CME symposium held during the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer blend practical perspectives with review of clinical trial data to address many of the most pertinent issues and education gaps faced by clinicians managing this unusual, challenging and heterogeneous disease.


    • Appreciate the importance of multidisciplinary collaboration in the diagnosis and management of gynecologic sarcomas, and use this information to design a process to optimize tissue procurement, accurate histological assessment, tertiary care referral and treatment outcome.
    • Develop an evidence-based strategy for the treatment of Stage I to III uterine sarcoma, considering the potential contributions of surgery, radiation therapy and/or cytotoxic therapy.
    • Employ guideline-endorsed monitoring protocols and techniques to effectively screen patients with localized uLMS for the development of metastases.
    • Recognize the role platelet-derived growth factor alpha (PDGFRα) expression plays in tumor proliferation and growth, and consider this information in the selection of therapeutic approach for patients with advanced uLMS.
    • Appraise available safety and efficacy data with approved targeted and cytotoxic therapies used in the treatment of advanced gynecologic sarcomas, and consider how these agents can be optimally incorporated into current clinical management algorithms.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Suzanne George, MD
    Clinical Director, Center for Sarcoma and Bone Oncology
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Blueprint Medicines, Deciphera Pharmaceuticals Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Deciphera Pharmaceuticals Inc, Pfizer Inc; Ownership Interest: Abbott Laboratories.

    Martee L Hensley, MD
    Attending, Gynecologic Medical Oncology
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Advisory Committee: Janssen Biotech Inc, Lilly; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc.

    David M O’Malley, MD
    Director, Clinical Research
    Gynecologic Oncology
    Co-Director, Gynecologic Oncology Phase I Program
    ORIEN Physician Liaison for OSUCCC-James
    The Ohio State University and The James Cancer Center
    Columbus, Ohio

    Advisory Committee: Amgen Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2018
    Expiration date: May 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):